TAT 2012 in Amsterdam, co-chaired by professors Henk Verheul (VUmc, Amsterdam) and Giuseppe Giaccone (NCI, Bethesda), was the tenth meeting in the series "International Congress on Targeted Anticancer Therapies". It was an ESMO Partnership Meeting, offered by the Amsterdam-based NDDO Education Foundation, and co-sponsored by the U.S. National Cancer Institute - Center for Cancer Research. 

TAT 2012 was attended by well over 400 delegates from over 40 countries worldwide, in particular Europe (69%) and North America (18%). The program encompassed some 50 plenary lectures and 70 posters. The program covered a broad range of contemporary issues in the identification and early-phase development of  the most promising targeted cancer therapeutics, as single agents or in combination with each other or with conventional anticancer agents.  

By their focus on targets and agents in late preclinical and early clinical development and the extensive involvement of the world's leading phase 1 investigators, TAT meetings offer a glimpse of the future of systemic cancer therapy. They provide clinical investigators and research scientists a place to meet and interact with their colleagues on new drugs and topics of common interest. Drug sponsors will get useful feedback on issues with which they may be struggling in their development programs. And physicians will get an early view of what is coming their way in terms of new cancer targets and agents affecting these targets. 

Abstracts presented at TAT 2012 are available online in Annals of Oncology (also accessible to non-subcribers). Presentations, to the extent presenting authors have given their consent, are available on this website. Click the button in the utmost right column to get access.  

Take a look at our picture gallery to get an impression of this unique oncology meeting, and keep following "the number 1 in phase 1" via the social media.